Authors


Virginia Martin, CPC, CHBC

Latest:

How to bill for a locum tenens during a transition period

There are different ways to go about billing for a locum tenens depending on your circumstances.


Adonis Hijaz, MD

Latest:

Opportunistic salpingectomy in female urologic surgery

Evidence suggests fallopian tube removal will lead to reduced ovarian cancer ­incidence.


Sam S. Chang, MD

Latest:

Cost considerations in the management of bladder cancer

"We will review the evidence and identify potential areas of improvement that can help reduce costs associated with UCB management while improving outcomes," write Daniel J. Lee, MD, and Sam S. Chang, MD.


Penny Allen

Latest:

Marijuana use prevalent among chronic prostatitis/chronic pelvic pain syndrome patients

With marijuana legalized for medical use in Canada since 2001 and now in 17 U.S. states and the District of Columbia, urology patients in pain have been turning to marijuana for relief.


Bob Gatty

Latest:

Report urges action on physician burnout

A new report by the National Academy of Medicine urges action by government, educational institutions, and health care organizations to address the causes of physician burnout, which is experienced by up to one-half of clinicians in the U.S. and threatens patient care.


Ray Painter, MD

Latest:

23 years of helping urologists play physicians’ Monopoly

I wanted to take this opportunity to say thank you to all who have read my “Coding and Reimbursement” and “Coding Q&A” articles for the past 23 years.


Mark Painter

Latest:

Medicare’s G2211 and thoughts on how to best use it in urology

"We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and we have had some experience using the code now that it is active and been able to observe some of the initial payment processing by the payer," write Jonathan Rubenstein, MD, and Mark Painter.


Peter C. Albertsen, MD

Latest:

Prostate cancer study highlights complexity of ‘appropriate’ care

"Deciding what care is appropriate is already extraordinarily difficult but will be a growing problem for the next generation of physicians and society," writes Peter C. Albertsen, MD.


Kathryn Foxhall

Latest:

'Medical home' gaining traction, but at what cost?

The controversial concept of medical home calls for a team led by a physician, usually a primary care physician, to be paid extra to handle personalized coordination of a patient's care across the health care system, including acting as liaison with other providers.


Peter Langenstroer, MD, MS

Latest:

Renal AML: The role of laparoscopic cryoablation

Five-year recurrence and disease-free survival rates for laparoscopic cryoablation are equivalent to those of standard open surgical techniques.


Andrew A. Wagner, MD

Latest:

Prostate cancer treatments: Assessing effects on quality of life

The most instructive HRQoL studies are those that rely on prospective, longitudinal assessments of patients using a validated instrument.


Martin G. Sanda, MD

Latest:

Prostate cancer treatments: Assessing effects on quality of life

The most instructive HRQoL studies are those that rely on prospective, longitudinal assessments of patients using a validated instrument.


Howard M. Snyder, III, MD

Latest:

Treatment of VUR: The bar is raised, morbidity lowered

The treatment paradigm for vesicoureteral reflux has undergone a significant shift in recent years. Endoscopic surgery has provided an effective, minimally invasive option that is gradually eliminating the need for prolonged antibiotic use, monitoring with voiding cystourethrograms (VCUGs), and open surgery in children with most grades and forms of VUR.


Leonard G. Gomella, MD

Latest:

Active Surveillance in Muscle Invasive Bladder Cancer

Types of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.


John T. Wei, MD, MS

Latest:

Prostate biopsies: How well do they predict tumor location?

Although needle biopsies are being used for localization, the majority of prostate cancers are multifocal in nature and invisible on gray scale ultrasonography.


Steven A. Kaplan, MD

Latest:

How to restart your practice when the COVID-19 red light turns green

"In the current environment of coronavirus disease 2019 (COVID-19), it has become obvious that it won’t be business as usual when the economy restarts and social distancing restrictions are relaxed," write Steven A. Kaplan, MD, and Alexis E. Te, MD.


S. Duke Herrell, MD

Latest:

Endoscopic robotic platforms: What the future holds

This article highlights some of the emerging endoscopic robotic systems in urology.


Ben H. Chew, MD, MSc

Latest:

Robotic ureteroscopy: The future of stone management?

Advances in robotic URS will help target stones and reduce ionizing radiation.


Louise Gagnon

Latest:

Good and bad news: ED patients often don't return

Quebec City, Quebec--The good news is that most patients being treated for erectile dysfunction report that their treatment is working. The bad news is that a significant percentage of these same patients are often lost to follow-up for that very reason, according to a study by urologists from McGill University.


Michael P. O'Leary, MD

Latest:

CP/CPPS therapies may yield long-sought answers

Research has begun to examine a range of novel treatment modalities, some with quite promising results.


Steven A. Kaplan, MD

Latest:

Nocturia: Data point to multiple etiologies

Recent studies suggest that nocturia has many etiologies, including urologic, metabolic, and perhaps most important, behavorial.


Timothy S. Ayers

Latest:

Stark II in 2003: What urologists still need to know

Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.


Marion Kristal Goldberg

Latest:

Stark II in 2003: What urologists still need to know

Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.


Stephen Y. Nakada, MD

Latest:

The physician executive: How one urologist balances MD, CEO roles

In this interview, physician executive J. Christian Winters, MD, outlines his multiple professional roles, explains how he divides his time between clinical and administrative responsibilities, and offers advice to young urologists seeking a career in leadership.


Thomas L. Mills

Latest:

Stark II in 2003: What urologists still need to know

Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.


Kevin T. McVary, MD

Latest:

The promise of PD-1 ligand pathway in treating bladder cancer

Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.


Thomas J. Walsh, MD

Latest:

Transgender surgery: Videos demonstrate cutting-edge techniques

In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.


Stefanie Petrou Binder, MD

Latest:

Botulinum formulations show slight outcomes differences

A new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.


Alice Goodman

Latest:

Adjuvant therapy fails in locally advanced kidney Ca

Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.


Robert A. Dowling, MD

Latest:

What Part B data reveal about BPH procedure usage

"As investigational therapies and devices make their way through the approval process and into practice, urologists should stay abreast of early clinical results and may look to publicly available information for costs and utilization trends," writes Robert A. Dowling, MD.

© 2024 MJH Life Sciences

All rights reserved.